Zydus Cadila’s Expansion in US market with acquisition of Sentynl Therapeutics Inc.

Zydus Cadila has forayed into the specialty pain market in the US valued at $ 8 billion with the acquisition of Sentynl Therapeutics Inc, a specialty pharma company that focuses on marketing of products in the pain management segment.

The deal will help Zydus to gain access to the specialty distribution network and a large prescriber base. Sentynl provides healthcare professionals with treatment solutions that enable them to meet the needs of individual patients. This acquisition will also enable the Zydus group to leverage its existing assets in the US.

Sentynl is a San Diego-based commercial-stage specialty pharma company which specialises in launching unique products and revitalising marketed brands. With a strong focus on specialised products, Sentynl sources niche and effective products designed to treat pain and other central nervous system (CNS) conditions.

The acquisition is solely funded by Bank of Tokyo-Mitsubishi UFJ. Leerink Partners LLC acted as exclusive financial advisor to Sentynl on the transaction.